Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites. Academic Article uri icon

Overview

abstract

  • BACKGROUND AND OBJECTIVES: Patients with metastatic RCC can undergo metastasectomy to improve survival time. Our goal was to provide and compare characteristics and oncological outcomes of RCC patients who underwent complete metastasectomy at a single organ site. METHODS: A total of 138 RCC patients were identified as undergoing complete metastasectomy at a single organ site including adrenal, lung, liver, pancreas, or thyroid. Competing risk regression analysis was used to assess RFS and CSS adjusting for several covariates. RESULTS: In this highly selected cohort, RFS and CSS was 27% and 84% at 5 years following metastasectomy, respectively. Univariate analysis revealed that removal of multiple tumors, younger age, and a shorter interval between nephrectomy and metastasis was associated with worse RFS. Larger tumors and sarcomatoid histology at nephrectomy was associated with worse CSS. We found no evidence that metastases at the time of RCC diagnosis influenced recurrence or survival. Tumor size, number of metastases resected, and time from nephrectomy to first recurrence was significantly different, but recurrence rates were not found to be significantly different, when compared across all organ sites. CONCLUSIONS: These findings inform clinical and surgical management of select RCC patients with isolated metastasis to one of several organ sites. J. Surg. Oncol. 2016;114:375-379. © 2016 Wiley Periodicals, Inc.

publication date

  • June 23, 2016

Research

keywords

  • Carcinoma, Renal Cell
  • Endocrine Gland Neoplasms
  • Liver Neoplasms
  • Lung Neoplasms
  • Metastasectomy

Identity

PubMed Central ID

  • PMC5104341

Scopus Document Identifier

  • 84983314477

Digital Object Identifier (DOI)

  • 10.1002/jso.24327

PubMed ID

  • 27338155

Additional Document Info

volume

  • 114

issue

  • 3